The clinicopathological and molecular characteristics of resected <i>EGFR</i> ‐mutant lung adenocarcinoma-Reference-Cited by-同舟云学术

The clinicopathological and molecular characteristics of resected EGFR ‐mutant lung adenocarcinoma

Published:2022-01-13 Issue:5 Volume:11 Page:1299-1309
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Zhou Wensheng¹²,Liu Zhichao²³^ORCID,Wang Yanan¹,Zhang Yanwei¹,Qian Fangfei¹,Lu Jun¹,Wang Huimin¹,Gu Ping¹,Hu Minjuan¹,Chen Ya¹,Yang Zhengyu¹,Zhao Ruiying⁴,Lou Yuqing¹,Han Baohui¹^ORCID,Zhang Wei¹^ORCID

Affiliation:

1. Department of Pulmonary Medicine Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai China

2. School of Medicine Shanghai Jiao Tong University Shanghai China

3. Department of Thoracic Surgery Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai China

4. Department of Pathology Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai China

Funder

Shanghai Hospital Development Center

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4543

Reference46 articles.

1. Cancer treatment and survivorship statistics, 2019

2. Genomic landscape of lung adenocarcinoma in East Asians

3. Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients

4. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma;Takamochi K;J Thorac Cardiovasc Surg,2017

5. Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TP53 and EGFR amplification are negative predictors of overall survival in patients diagnosed with non-small cell lung cancer with brain metastases;Heliyon;2024-08

2. PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities;Pharmacological Research;2024-04

3. Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives;Journal of Thoracic Oncology;2023-11

4. Prognosis of recurrence after complete resection in early-stage lung adenocarcinoma based on molecular alterations: a systematic review and meta-analysis;Scientific Reports;2023-10-31

5. A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer;Cancers;2023-09-14